Abstract
The Aim of the en-ABL e-registry is to evaluate safety and efficacy of ABLUMINUS DES (Sirolimus Eluting Stent) in diabetic patients vs. non diabetic patients. The en-ABL e-registry is a prospective, real world, all-comers, multicenter registry. Overall, 2500 patients have been enrolled. Among them
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
